Literature DB >> 19531579

A history of atrial fibrillation and outcomes in chronic advanced systolic heart failure: a propensity-matched study.

Mustafa I Ahmed1, Michel White, O James Ekundayo, Thomas E Love, Inmaculada Aban, Bo Liu, Wilbert S Aronow, Ali Ahmed.   

Abstract

AIMS: Atrial fibrillation (AF)-associated poor outcomes in heart failure (HF) are often attributed to older age, advanced disease, and comorbidity burden of HF patients with AF. Therefore, we examined the effect of AF on outcomes in a propensity-matched study in which patients with and without AF were well balanced on all measured baseline characteristics. METHODS AND
RESULTS: Of the 2708 advanced chronic systolic HF patients in the Beta-Blocker Evaluation of Survival Trial, 653 had a history of AF. Propensity scores for AF were calculated for each patient and were used to assemble a cohort of 487 pairs of patients with and without AF who were balanced on 74 baseline characteristics. Matched Cox regression analyses were used to estimate associations of AF with outcomes during 23 months of mean follow-up. All-cause mortality occurred in 187 (rate, 2046/10,000 person-years of follow-up) and 181 (rate, 1885/10,000 person-years) matched patients with and without AF, respectively [matched hazard ratio (HR) when AF was compared with no-AF 1.03, 95% confidence interval (CI) 0.79-1.33; P = 0.84]. Heart failure hospitalization occurred in 215 (rate, 3171/10,000 person-years) and 184 (rate, 2405/10,000 person-years) matched patients with and without AF, respectively (matched HR when AF was compared with no-AF 1.28, 95% CI 1.00-1.63; P = 0.049). Hazard ratios and 95% CIs for AF-associated HF hospitalization for bucindolol and placebo groups were, respectively, 1.08 (0.81-1.43) and 1.54 (1.17-2.03; P for interaction = 0.09).
CONCLUSION: A history of AF had no intrinsic association with mortality but was associated with HF hospitalization in chronic systolic HF.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19531579      PMCID: PMC2726959          DOI: 10.1093/eurheartj/ehp222

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  22 in total

1.  Confounding: regression adjustment.

Authors:  Garrett Fitzmaurice
Journal:  Nutrition       Date:  2006-05       Impact factor: 4.008

2.  Hemodynamic effects of an irregular sequence of ventricular cycle lengths during atrial fibrillation.

Authors:  D M Clark; V J Plumb; A E Epstein; G N Kay
Journal:  J Am Coll Cardiol       Date:  1997-10       Impact factor: 24.094

3.  Comparison of plasma neurohormones in congestive heart failure patients with atrial fibrillation versus patients with sinus rhythm.

Authors:  A E Tuinenburg; D J Van Veldhuisen; F Boomsma; M P Van Den Berg; P J De Kam; H J Crijns
Journal:  Am J Cardiol       Date:  1998-05-15       Impact factor: 2.778

4.  Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial.

Authors:  Ali Ahmed; Michael W Rich; Thomas E Love; Donald M Lloyd-Jones; Inmaculada B Aban; Wilson S Colucci; Kirkwood F Adams; Mihai Gheorghiade
Journal:  Eur Heart J       Date:  2005-12-08       Impact factor: 29.983

5.  ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society.

Authors:  Sharon Ann Hunt; William T Abraham; Marshall H Chin; Arthur M Feldman; Gary S Francis; Theodore G Ganiats; Mariell Jessup; Marvin A Konstam; Donna M Mancini; Keith Michl; John A Oates; Peter S Rahko; Marc A Silver; Lynne Warner Stevenson; Clyde W Yancy; Elliott M Antman; Sidney C Smith; Cynthia D Adams; Jeffrey L Anderson; David P Faxon; Valentin Fuster; Jonathan L Halperin; Loren F Hiratzka; Alice K Jacobs; Rick Nishimura; Joseph P Ornato; Richard L Page; Barbara Riegel
Journal:  Circulation       Date:  2005-09-13       Impact factor: 29.690

6.  Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program.

Authors:  Lars G Olsson; Karl Swedberg; Anique Ducharme; Christopher B Granger; Eric L Michelson; John J V McMurray; Margareta Puu; Salim Yusuf; Marc A Pfeffer
Journal:  J Am Coll Cardiol       Date:  2006-04-27       Impact factor: 24.094

7.  Chronic kidney disease associated mortality in diastolic versus systolic heart failure: a propensity matched study.

Authors:  Ali Ahmed; Michael W Rich; Paul W Sanders; Gilbert J Perry; George L Bakris; Michael R Zile; Thomas E Love; Inmaculada B Aban; Michael G Shlipak
Journal:  Am J Cardiol       Date:  2006-12-08       Impact factor: 2.778

8.  Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods.

Authors:  Ali Ahmed; Ahsan Husain; Thomas E Love; Giovanni Gambassi; Louis J Dell'Italia; Gary S Francis; Mihai Gheorghiade; Richard M Allman; Sreelatha Meleth; Robert C Bourge
Journal:  Eur Heart J       Date:  2006-05-18       Impact factor: 29.983

9.  Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens.

Authors:  R Farshi; D Kistner; J S Sarma; J A Longmate; B N Singh
Journal:  J Am Coll Cardiol       Date:  1999-02       Impact factor: 24.094

10.  Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies.

Authors:  R Clarke; M Shipley; S Lewington; L Youngman; R Collins; M Marmot; R Peto
Journal:  Am J Epidemiol       Date:  1999-08-15       Impact factor: 4.897

View more
  32 in total

1.  Impairment of activities of daily living and incident heart failure in community-dwelling older adults.

Authors:  C Barrett Bowling; Gregg C Fonarow; Kanan Patel; Yan Zhang; Margaret A Feller; Xuemei Sui; Steven N Blair; Kannayiram Alagiakrishnan; Inmaculada B Aban; Thomas E Love; Richard M Allman; Ali Ahmed
Journal:  Eur J Heart Fail       Date:  2012-04-04       Impact factor: 15.534

2.  Uncontrolled hypertension and increased risk for incident heart failure in older adults with hypertension: findings from a propensity-matched prospective population study.

Authors:  Anand S Iyer; Mustafa I Ahmed; Gerasimos S Filippatos; O James Ekundayo; Inmaculada B Aban; Thomas E Love; Navin C Nanda; George L Bakris; Gregg C Fonarow; Wilbert S Aronow; Ali Ahmed
Journal:  J Am Soc Hypertens       Date:  2010 Jan-Feb

3.  Atrial fibrillation: a leading cause of heart failure-related hospitalizations; a dual epidemic.

Authors:  Asrar Ahmed; Waqas Ullah; Ishtiaq Hussain; Sohaib Roomi; Yasar Sattar; Faizan Ahmed; Rehan Saeed; Ammar Ashfaq
Journal:  Am J Cardiovasc Dis       Date:  2019-10-15

4.  Association of 30-Day All-Cause Readmission with Long-Term Outcomes in Hospitalized Older Medicare Beneficiaries with Heart Failure.

Authors:  Cherinne Arundel; Phillip H Lam; Rahul Khosla; Marc R Blackman; Gregg C Fonarow; Charity Morgan; Qing Zeng; Ross D Fletcher; Javed Butler; Wen-Chih Wu; Prakash Deedwania; Thomas E Love; Michel White; Wilbert S Aronow; Stefan D Anker; Richard M Allman; Ali Ahmed
Journal:  Am J Med       Date:  2016-07-09       Impact factor: 4.965

5.  Association of obesity and survival in systolic heart failure after acute myocardial infarction: potential confounding by age.

Authors:  Audrey H Wu; Bertram Pitt; Stefan D Anker; John Vincent; Marjan Mujib; Ali Ahmed
Journal:  Eur J Heart Fail       Date:  2010-03-30       Impact factor: 15.534

6.  Rate-control versus rhythm-control strategies and outcomes in septuagenarians with atrial fibrillation.

Authors:  Nasir Shariff; Ravi V Desai; Kanan Patel; Mustafa I Ahmed; Gregg C Fonarow; Michael W Rich; Inmaculada B Aban; Maciej Banach; Thomas E Love; Michel White; Wilbert S Aronow; Andrew E Epstein; Ali Ahmed
Journal:  Am J Med       Date:  2013-10       Impact factor: 4.965

7.  Characteristics and outcomes of patients with advanced chronic systolic heart failure receiving care at the Veterans Affairs versus other hospitals: insights from the Beta-blocker Evaluation of Survival Trial (BEST).

Authors:  Linda G Jones; Mo-Kyung Sin; Fadi G Hage; Raya E Kheirbek; Charity J Morgan; Michael R Zile; Wen-Chih Wu; Prakash Deedwania; Gregg C Fonarow; Wilbert S Aronow; Sumanth D Prabhu; Ross D Fletcher; Ali Ahmed; Richard M Allman
Journal:  Circ Heart Fail       Date:  2014-12-05       Impact factor: 8.790

8.  Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation.

Authors:  David P Kao; Gordon Davis; Ryan Aleong; Christopher M O'Connor; Mona Fiuzat; Peter E Carson; Inder S Anand; Jonathan F Plehn; Stephen S Gottlieb; Marc A Silver; JoAnn Lindenfeld; Alan B Miller; Michel White; Guinevere A Murphy; Will Sauer; Michael R Bristow
Journal:  Eur J Heart Fail       Date:  2012-12-07       Impact factor: 15.534

9.  Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial.

Authors:  Mihai Gheorghiade; Gregg C Fonarow; Dirk J van Veldhuisen; John G F Cleland; Javed Butler; Andrew E Epstein; Kanan Patel; Inmaculada B Aban; Wilbert S Aronow; Stefan D Anker; Ali Ahmed
Journal:  Eur Heart J       Date:  2013-04-16       Impact factor: 29.983

10.  Renin-angiotensin inhibition in diastolic heart failure and chronic kidney disease.

Authors:  Ali Ahmed; Michael W Rich; Michael Zile; Paul W Sanders; Kanan Patel; Yan Zhang; Inmaculada B Aban; Thomas E Love; Gregg C Fonarow; Wilbert S Aronow; Richard M Allman
Journal:  Am J Med       Date:  2013-02       Impact factor: 4.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.